Genmab is dealing with multiple strategic changes in markets. The company recently initiated a
share buy-back program advancing it numerous times and has also granted restricted stock units and warrants to employees. Genmab has faced multiple stock value fluctuations, with a new 12-month low at
$26.32, and has experienced a sale of shares by a board member. Despite these turbulence, investors have seen
respectable returns of 82% over the past five years. The company recently acquired
ProfoundBio for $1.8 billion, a developer of an Ovarian Cancer drug. Various significant shareholders, including Royal London Asset Management and Franklin Resources, have sold substantial numbers of Genmab shares. However, firms like Lighthouse Investment Partners and First Trust Advisors have increased their positions. While the stock's price has fluctuated, analysts' ratings illustrate a mixed sentiment, with some maintaining a 'hold' stance and others asserting a 'buy'. In the wake of the recent kr.4.1b drop, Genmab might face pressure from institutional owners. Despite encountering a loss in arbitration, Genmab reported strong
DARZALEX sales in Q1 2024. It seems Genmab's value experienced a significant boost after its share buyback.
Genmab Stocks News Analytics from Fri, 08 Feb 2019 02:07:50 GMT to Sun, 16 Jun 2024 05:41:34 GMT -
Rating 0
- Innovation 2
- Information 7
- Rumor 2
